Basic research funding by philanthropic organizations: A case in point

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 11, 2013, Pages 1376-1378

  Chignard, Michel ^a   Ramphal, Reuben ^b,c  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c Université Franaois Rabelais   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; KALYEDO; LUMACAFTOR; MUTANT PROTEIN; UNCLASSIFIED DRUG;

BASIC RESEARCH; CELL FATE; CELL MEMBRANE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG COST; ENDOPLASMIC RETICULUM; FORCED EXPIRATORY VOLUME; FUNDING; GENE SEQUENCE; GENE THERAPY; HOMOZYGOTE; HUMAN; LETTER; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; LUNG FUNCTION TEST; MECONIUM ILEUS; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSLATIONAL RESEARCH; WEIGHT GAIN;

EID: 84890012305     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1275LE     Document Type: Letter

References (10)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003.
2. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365: 1663-1672.
3. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065.
4. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
5. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080.
6. Min Jou W, Haegeman G, Ysebaert M, Fiers W. Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein. Nature 1972; 237:82-88.
7. Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, Kazazian HH Jr. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 1990;346:366-369.
8. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Durie P, Tsui LC, McIntosh I, Keston M, Brock DJ, et al. Cystic fibrosis patients bearing both the common missense mutation GlyAsp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. Am J Hum Genet 1992;51:245-250.
9. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100:2457-2465.
10. Clunes MT, Boucher RC. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008;8:292-299.